14-day Premium Trial Subscription Sign Up For FreeGet Free

Amgen Inc. Stock Forecast NASDAQ:AMGN

Price Target and Analyst Ratings

Most Recent Rating

On September 17, 2021 "William Blair" gave "" rating for AMGN. The price target was set to $217.41+0.0%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-09-17 Reiterated by William Blair $217.36 $217.41+0.0%
2021-09-10 $222.00 Initiated by Mizuho $213.75 $215.31→0.1%
2021-09-07 $280.00 - $251.00 Downgraded by Morgan Stanley $221.34 $226.37+0.2%
2021-08-05 Reiterated by Robert W. Baird $233.99 $228.31→6.5%
2021-08-04 $238.00 - $234.00 Target Lowered by SVB Leerink $228.31 $244.08+1.8%
2021-07-28 $185.00 Reiterated by Robert W. Baird $244.25 $244.68→0.2%
2021-07-16 $278.00 - $280.00 Target Raised by Morgan Stanley $247.96 $248.63+0.8%
2021-06-25 Hold Reiterated by Mizuho $242.68 $200.00
2021-06-07 Outperform Target Raised by Oppenheimer $237.19 $272.00 → $277.00
2021-06-07 Market Perform Target Raised by SVB Leerink $237.19 $230.00 → $238.00
2021-05-31 Positive - Outperform Target Raised by BMO Capital Markets $237.94 $296.00 → $301.00
2021-05-17 Buy Reiterated by Oppenheimer $252.38 $270.00
2021-05-10 Outperform Target Lowered by Oppenheimer $252.62 $275.00 → $265.00
2021-05-04 Neutral - Underweight Reiterated by Atlantic Securities $247.36 $200.00
2021-05-04 Market Perform Target Lowered by SVB Leerink $247.36 $267.00 → $230.00
2021-05-04 Sector Perform Target Lowered by Royal Bank of Canada $247.36 $220.00 → $217.00
2021-05-04 Outperform Target Lowered by Credit Suisse Group $247.36 $265.00 → $259.00
2021-05-03 Outperform Target Lowered by Oppenheimer $245.38 $275.00 → $265.00
2021-05-03 Overweight Target Lowered by Morgan Stanley $245.38 $281.00 → $278.00
2021-04-29 Buy Reiterated by Evercore ISI $234.71
2021-04-29 Sell Reiterated by Robert W. Baird $234.71
2021-04-28 Neutral - Underweight Downgraded by Atlantic Securities $236.71
2021-04-28 Outperform Target Lowered by BMO Capital Markets $236.71 $301.00 → $296.00
2021-04-28 Neutral Target Set by JPMorgan Chase & Co. $236.71 $215.00
2021-04-28 Buy Target Set by The Goldman Sachs Group $236.71 $290.00
2021-04-28 Sector Perform Target Lowered by Royal Bank of Canada $236.71 $220.00 → $217.00
2021-04-28 Buy Reiterated by The Goldman Sachs Group $236.71 $290.00
2021-04-28 Market Perform Target Lowered by SVB Leerink $236.71 $267.00 → $230.00
2021-04-28 Outperform Target Lowered by Credit Suisse Group $236.71 $265.00 → $259.00
2021-04-28 Neutral Reiterated by JPMorgan Chase & Co. $236.71 $215.00
2021-04-28 Neutral - Underweight Downgraded by Atlantic Securities $236.71 $200.00
2021-04-26 Overweight Target Lowered by Morgan Stanley $255.52 $281.00 → $278.00
2021-04-26 Overweight Target Raised by Morgan Stanley $255.52 $279.00 → $281.00
2021-04-19 Overweight Target Raised by Morgan Stanley $255.97 $279.00 → $281.00
2021-04-05 Target Raised by Oppenheimer $252.02 $266.00 → $275.00
2021-03-11 Equal Weight Target Lowered by Barclays $231.17 $242.00 → $230.00
2021-03-11 Overweight Target Raised by Morgan Stanley $231.17 $277.00 → $279.00
2021-03-08 Market Perform Target Raised by SVB Leerink $227.81 $252.00 → $260.00
2021-03-05 Overweight Target Raised by Morgan Stanley $227.73 $277.00 → $279.00
2021-03-05 Equal Weight Target Lowered by Barclays $227.73 $242.00 → $230.00
2021-03-04 Neutral Target Set by JPMorgan Chase & Co. $221.91 $222.00
2021-03-04 Buy Target Set by The Goldman Sachs Group $221.91 $277.00
2021-03-01 Market Perform Target Raised by SVB Leerink $227.04 $245.00 → $252.00
2021-02-03 Market Perform Target Lowered by SVB Leerink $237.08 $253.00 → $245.00
2021-02-03 Overweight Target Lowered by Piper Sandler $237.08 $280.00 → $260.00
2021-02-03 Outperform Target Lowered by Credit Suisse Group $237.08 $280.00 → $265.00
2021-02-03 Overweight Target Lowered by Morgan Stanley $237.08 $285.00 → $277.00
2021-02-03 Positive - Overweight Target Raised by Cantor Fitzgerald $237.08 $280.00 → $295.00
2021-01-31 Buy Reiterated by Oppenheimer $241.43 $266.00
2021-01-19 Overweight Target Raised by Morgan Stanley $248.27 $276.00 → $285.00
2021-01-04 Neutral Reiterated by Royal Bank of Canada $226.66
2020-12-29 Buy Initiated by Daiwa Capital Markets $226.87 $300.00
2020-12-29 Neutral Reiterated by Royal Bank of Canada $226.87
2020-12-27 Buy Initiated by Oppenheimer $222.93 $266.00
2020-12-27 Hold Reiterated by JPMorgan Chase & Co. $222.93
2020-12-23 Neutral Reiterated by Royal Bank of Canada $222.94
2020-12-16 Overweight Target Raised by Morgan Stanley $228.44 $275.00 → $276.00
2020-12-15 Conviction-Buy - Buy Downgraded by The Goldman Sachs Group $230.53
2020-12-09 Market Perform Target Raised by SVB Leerink $229.85 $243.00 → $253.00
2020-12-08 Overweight Target Raised by Piper Sandler $228.94 $270.00 → $280.00
2020-11-16 Outperform Target Lowered by Oppenheimer $236.66 $280.00 → $274.00
2020-11-11 Buy Initiated by Oppenheimer $240.69 $280.00
2020-11-02 Neutral Target Lowered by Mizuho $220.21 $260.00 → $215.00
2020-10-29 Overweight Target Lowered by Cantor Fitzgerald $217.82 $279.00 → $278.00
2020-10-29 Outperform Target Lowered by BMO Capital Markets $217.82 $308.00 → $304.00
2020-10-29 Neutral Target Lowered by JPMorgan Chase & Co. $217.82 $232.00 → $222.00
2020-10-29 Market Perform Target Lowered by SVB Leerink $217.82 $261.00 → $243.00
2020-10-29 Buy Target Lowered by Bank of America $217.82 $275.00 → $265.00
2020-10-29 Market Perform - Overweight Target Raised by Morgan Stanley $217.82 $273.00 → $275.00
2020-10-29 Equal Weight Target Lowered by Barclays $217.82 $250.00 → $242.00
2020-10-28 Neutral Initiated by UBS Group $216.38 $232.00
2020-10-27 Outperform Target Lowered by Credit Suisse Group $223.46 $286.00 → $284.00
2020-10-26 Market Perform - Outperform Upgraded by Raymond James $224.89 $255.00
2020-10-22 Outperform Target Lowered by Oppenheimer $227.98 $280.00 → $275.00
2020-10-15 Hold Reiterated by Royal Bank of Canada $235.01 $223.00
2020-10-13 Overweight Target Lowered by Morgan Stanley $239.34 $281.00 → $273.00
2020-10-12 Hold - Buy Upgraded by Truist $239.51
2020-10-09 Buy - Hold Downgraded by Truist $236.70 $251.00
2020-10-09 Outperform - Market Perform Downgraded by Sanford C. Bernstein $236.70
2020-10-06 Buy Reiterated by Raymond James $252.69
2020-10-06 Positive - Outperform Target Raised by Oppenheimer $252.69 $270.00 → $280.00
2020-10-06 Buy Reiterated by Oppenheimer $252.69 $280.00
2020-09-23 Hold Reiterated by William Blair $242.59
2020-09-22 Hold Reiterated by JPMorgan Chase & Co. $247.50
2020-09-21 Buy Reiterated by Oppenheimer $243.19 $270.00
2020-07-29 Buy Target Raised by Jefferies Financial Group $248.85 $285.00 → $300.00
2020-07-29 Equal Weight - In-Line Target Raised by Wells Fargo & Co $248.85 $237.00 → $247.00
2020-07-29 Sector Perform Target Lowered by Royal Bank of Canada $248.85 $236.00 → $223.00
2020-07-29 Equal Weight Target Raised by Barclays $248.85 $245.00 → $250.00
2020-07-29 Overweight Target Lowered by Morgan Stanley $248.85 $285.00 → $281.00
2020-07-29 Buy Reiterated by Credit Suisse Group $248.85
2020-07-29 Market Perform Target Raised by SVB Leerink $248.85 $253.00 → $261.00
2020-07-29 Overweight Target Raised by Cantor Fitzgerald $248.85 $263.00 → $279.00
2020-07-28 Neutral Target Raised by JPMorgan Chase & Co. $255.27 $225.00 → $232.00
2020-07-28 Positive - Overweight Target Raised by Piper Sandler $255.27 $255.00 → $270.00
2020-07-20 Outperform Target Raised by Credit Suisse Group $260.95 $252.00 → $290.00
2020-07-20 Outperform Target Raised by Oppenheimer $260.95 $252.00 → $265.00
2020-07-15 Overweight Target Raised by Morgan Stanley $253.31 $280.00 → $285.00
2020-06-18 Neutral Target Raised by JPMorgan Chase & Co. $230.32 $219.00 → $225.00
2020-06-02 Market Perform Target Raised by SVB Leerink $223.72 $249.00 → $253.00

AMGN Stock Trend

The stock lies in the middle of a falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -12.01% during the next 3 months and, with a 90% probability hold a price between $186.33 and $201.38 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-09-20 $211.27 $219.82 $228.37
2021-09-21 $210.77 $219.33 $227.88
2021-09-22 $210.28 $218.83 $227.38
2021-09-23 $209.78 $218.33 $226.88
2021-09-24 $209.29 $217.84 $226.39
2021-09-27 $208.79 $217.34 $225.89
2021-09-28 $208.29 $216.84 $225.40
2021-09-29 $207.80 $216.35 $224.90
2021-09-30 $207.30 $215.85 $224.40
2021-10-01 $206.80 $215.36 $223.91
2021-10-04 $206.31 $214.86 $223.41
2021-10-05 $205.81 $214.36 $222.92
2021-10-06 $205.32 $213.87 $222.42
2021-10-07 $204.82 $213.37 $221.92
2021-10-08 $204.32 $212.88 $221.43
2021-10-11 $203.83 $212.38 $220.93
2021-10-12 $203.33 $211.88 $220.44
2021-10-13 $202.84 $211.39 $219.94
2021-10-14 $202.34 $210.89 $219.44
2021-10-15 $201.84 $210.40 $218.95
2021-10-18 $201.35 $209.90 $218.45
2021-10-19 $200.85 $209.40 $217.96
2021-10-20 $200.36 $208.91 $217.46
2021-10-21 $199.86 $208.41 $216.96
2021-10-22 $199.36 $207.92 $216.47
2021-10-25 $198.87 $207.42 $215.97
2021-10-26 $198.37 $206.92 $215.48
2021-10-27 $197.88 $206.43 $214.98
2021-10-28 $197.38 $205.93 $214.48
2021-10-29 $196.88 $205.44 $213.99

About Amgen Inc.

Amgen Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a rec... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT